Back to top

Image: Bigstock

Nektar Therapeutics

Read MoreHide Full Article

The launches of Movantik and Adynovate have been on track with both the products performing impressively. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which will boost its financial position significantly. Nektar also has a deep and promising pipeline, with several updates lined up for the next several quarters, which could act as growth catalysts. If the company’s partnered programs are successful, they could contribute to royalty streams as early as the end of 2017. However, Nektar relies heavily on partners for top-line growth. Partnership-related setbacks may weigh heavily on the company, and disappointing products sales could have a significant impact on its financial results. Shares of the company have underperformed the Medical-Drugs industry in 2016. Estimates have also come down ahead of the company's fourth-quarter 2016 results.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Nektar Therapeutics (NKTR) - free report >>

Published in